Exagen's Q3 results revealed a 7% year-over-year revenue growth but an 8% sequential decline, with gross margin dropping to 58.8% and operating expenses up 16%. These figures raise concerns about the company's turnaround progress despite new growth initiatives like myositis launch, Pharma Services, and AI software. While these initiatives offer potential, they require time and effective execution to improve profitability, leading to the stock being downgraded to Hold.
Exagen's Q3 results provide context for readers. For those following the health sector, 99 of 150 US stocks rose today on Pluang. Notable movers include SLS at USD 8.97 (+11.71%), FLNA at USD 0.48 (+7.05%, 87% buy orders), and HRTX at USD 0.35 (+5.80%) as of Nov 13, 2026 19:41 WIB.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
